Conditions: HIV Infections
Keywords: Raltegravir CSF ABCB1 SNP HIV/AIDS
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 40
Healthy volunteers: yes

Brief summary:
This study is being done to find out how much of the drug raltegravir (RGV) gets into cerebrospinal fluid (CSF), compared to how much get into the blood and to find out if normal changes in a certain gene in your body affects how much RGV gets into the CSF.

Detailed description:
The multidrug efflux transporter P-glycoprotein (P-gp) is expressed in the blood-brain barrier where it limits entry of substrate drugs into the central nervous system. Raltegravir (MK-0158), a new HIV-1 integrase inhibitor and potentially major addition to the therapeutic armamentarium against HIV, is a substrate for P-gp. Studies are warranted to elucidate the relevance of P-gp transport for raltegravir in the central nervous system.

Arms:
arm 1: Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.

Interventions: intervention 1: Raltegravir
Intervention descriptions: intervention 1: 400mg orally every 12 hours for 7 days

Protocol document: